Empirical Asset Management LLC Boosts Position in Amgen Inc. $AMGN

Empirical Asset Management LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 92.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,925 shares of the medical research company’s stock after buying an additional 1,403 shares during the quarter. Empirical Asset Management LLC’s holdings in Amgen were worth $1,059,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Dogwood Wealth Management LLC lifted its holdings in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares in the last quarter. Anfield Capital Management LLC increased its stake in shares of Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after purchasing an additional 70 shares in the last quarter. Tower View Wealth Management LLC raised its position in shares of Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after purchasing an additional 63 shares during the last quarter. Manning & Napier Advisors LLC lifted its stake in Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after buying an additional 32 shares in the last quarter. Finally, Ares Financial Consulting LLC purchased a new stake in Amgen in the 4th quarter valued at approximately $34,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by corporate insiders.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen was highlighted as one of the best-performing U.S. large-cap drugmakers in 2026, outperforming peers Merck and Pfizer despite lacking an obesity drug. The comparison reinforces investor confidence in Amgen’s existing portfolio and operating execution. Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?
• Positive Sentiment: Healthcare-sector strength and a rotation toward profitable drugmakers helped lift Amgen, while renewed enthusiasm for biotechnology also improved sentiment across the industry. Amgen Stock Surges as Healthcare Hits Record High
• Positive Sentiment: Argus raised its Amgen price target from $375 to $460 and maintained a “buy” rating, citing additional upside for the shares. Argus price-target update
• Neutral Sentiment: Amgen’s latest quarterly results beat consensus estimates for earnings and revenue, with revenue growth accelerating year over year. Full-year earnings guidance and expectations for continued growth remain important supports for the investment case.
• Neutral Sentiment: The obesity-drug market is becoming more selective, and Amgen is reportedly trimming some early-stage efforts. This could improve capital discipline, but it also highlights execution risk as the company competes in a crowded field. Obesity investing’s way forward, mapped
• Negative Sentiment: Although Cantor Fitzgerald and Mizuho raised their price targets, both retained “neutral” ratings and set targets below the current trading level, signaling valuation concerns after Amgen’s strong run. Analyst price-target updates

Analyst Ratings Changes

Several equities analysts have weighed in on AMGN shares. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Robert W. Baird upped their price objective on Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. UBS Group increased their price objective on Amgen from $420.00 to $440.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Canaccord Genuity Group lifted their price objective on Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Finally, Wells Fargo & Company boosted their target price on shares of Amgen from $390.00 to $400.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $379.36.

Amgen Trading Up 4.0%

Shares of AMGN opened at $442.36 on Thursday. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $443.20. The company has a market capitalization of $239.15 billion, a PE ratio of 27.49, a price-to-earnings-growth ratio of 3.95 and a beta of 0.41. The stock has a fifty day moving average of $375.75 and a two-hundred day moving average of $360.76. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. The business had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The business’s revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the firm earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, analysts forecast that Amgen Inc. will post 22.78 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio (DPR) is presently 62.65%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.